On 2 October 2026 the FDA approved a supplement to the new drug application for pirtobrutinib (Jaypirca), held by Loxo Oncology. The notice does not state what the supplement changes; supplements can cover labelling, dosing, manufacturing or new indications.
Pirtobrutinib is a non-covalent BTK inhibitor used in B-cell malignancies. Until the label change is published, prescribers should not assume any new indication or dosing advice. Its status with CDSCO is not stated in this notice.
- The notice confirms an approved supplement but not its content.
- Check the updated FDA label before changing practice.
- As with other BTK inhibitors, review interacting CYP3A drugs and bleeding risk with anticoagulants or antiplatelets.
- Indian regulatory status is not addressed by this notice.
Why it matters
BTK inhibitor labels carry interaction and bleeding advice that clinical pharmacologists are asked about.
Don't overread it
A licence supplement is not, on its own, a new indication.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free